文献速递神经肌肉病

糖皮质激素治疗杜氏肌营养不良患者的双膦酸盐应用:系统综述与证据分级

Bisphosphonates in Glucocorticoid-Treated Patients With Duchenne Muscular Dystrophy: A Systematic Review and Grading of the Evidence.
PubMed 文献 · Neurology · 2023-12-18

本系统综述检索至2023年3月31日,纳入19篇文献共1010例来自12个国家的儿童和成人患者,评估双膦酸盐在糖皮质激素治疗的杜氏肌营养不良患者中的获益与危害证据。高质量证据表明双膦酸盐可显著提高腰椎面积骨密度Z评分,骨折风险获益证据不确定或质量低,药物总体耐受良好但首次输注相关急性期反应常见。

要点

  • 高质量证据支持双膦酸盐可提高糖皮质激素治疗杜氏肌营养不良患者的腰椎面积骨密度Z评分。
  • 骨折风险获益证据不确定或质量低,主要因缺乏对照数据和小样本。
  • 双膦酸盐总体耐受良好,但首次输注相关急性期反应常见。

核心结论

  • 有高质量证据支持使用双膦酸盐提高杜氏肌营养不良合并糖皮质激素性骨质疏松患者的腰椎面积骨密度Z评分。
  • 本综述与分级证实了2018年杜氏肌营养不良临床照护考虑中提出的当前推荐。
  • 本综述有助于提高对双膦酸盐预期获益、未满足需求和潜在安全问题的认识。

研究设计与样本

  • 系统综述,PROSPERO注册号CRD42020157606,检索MEDLINE、CINAHL、Embase、PsycINFO、Web of Science和CENTRAL,从建库至2023年3月31日,不限语言和研究类型。
  • 纳入19篇出版物,涉及来自12个国家的1010名儿童和成人,覆盖除南美洲外所有有人居住的大洲。
  • 使用推荐分级的评估、制定与评价框架评估证据质量。

主要发现

  • 高质量证据表明双膦酸盐显著提高糖皮质激素治疗的杜氏肌营养不良患者的腰椎面积骨密度Z评分。
  • 最大改善记录于对照环境中接受静脉唑来膦酸治疗的患者。
  • 骨折风险获益证据不确定或质量低,主要因缺乏对照数据和小样本。
  • 双膦酸盐总体耐受良好,但首次输注相关不良事件(即「急性期反应」)频繁报告。

临床怎么用

  • 本综述与分级证实2018年杜氏肌营养不良临床照护考虑中提出的当前推荐。
  • 本综述有助于提高对双膦酸盐预期获益、未满足需求和潜在安全问题的认识。

局限性

  • 骨折风险获益证据不确定或质量低,主要因缺乏对照数据和小样本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Bisphosphonates are routinely used to treat osteoporosis in patients with Duchenne muscular dystrophy (DMD), a rare, severely debilitating neuromuscular disease. We sought to synthesize and grade benefits and harms evidence of bisphosphonates in glucocorticoid-treated patients with DMD. METHODS: In this systematic review (PROSPERO identifier: CRD42020157606), we searched MEDLINE, CINAHL, Embase, PsycINFO, Web of Science, and CENTRAL for articles published from inception up to and including March 31, 2023, reporting results in any language from any study type. Quality of evidence was assessed using the Grading of Recommendations, Assessment, Development, and Evaluations framework. RESULTS: We identified 19 publications involving 1,010 children and adults from 12 countries across all inhabited continents except South America. We found high-quality evidence that bisphosphonates significantly increase the areal lumbar spine bone mineral density (BMD) Z score in glucocorticoid-treated patients with DMD. The greatest improvements were recorded in controlled settings among patients treated with intravenous zoledronate. Evidence of benefits to fracture risks was inconclusive and/or of low quality, primarily due to lack of controlled data and small samples. Bisphosphonates were generally well-tolerated, although adverse events related to the first infusion (i.e., "acute phase reaction") were frequently reported. DISCUSSION: There is high-quality evidence supporting the use of bisphosphonates to increase the areal lumbar spine BMD Z score in patients with DMD and glucocorticoid-induced osteoporosis. Our synthesis and grading affirm current recommendations put forward in the 2018 DMD Clinical Care Considerations and should be helpful in raising awareness about anticipated benefits of bisphosphonates, prevailing unmet needs, and potential safety issues in their use.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Landfeldt E, Phung K, Zaman F, et al. Bisphosphonates in Glucocorticoid-Treated Patients With Duchenne Muscular Dystrophy: A Systematic Review and Grading of the Evidence. Neurology. 2023. PMID: 38165327. doi:10.1212/WNL.0000000000207948

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。